First HAART in HIV-Infected Patients With High Viral Load: Value of HIV RNA Levels at 12 Weeks to Predict Virologic Outcome

Abstract

The aim of this study is to identify the role of incomplete suppression during the first months of highly active antiretroviral treatment (HAART) to predict virologic failure in patients with high levels of HIV replication. In a retrospective, longitudinal, and multicenter study, response to HAART was assessed in treatment-naive adults with HIV RNA >100 000 copies/mL, and factors predicting failure were analyzed through regression analyses. A total of 118 patients were included. Virologic failure occurred more often in patients with >500 copies/mL at week 12 (Cox regression: Exp (B) 3.22; P = .02). HIV RNA >500 copies/mL at week 12 predicted incomplete virologic response (odds ratio [OR] = 9.33; P = .002] but not viral rebound. Major antiretroviral resistant mutations were present in 11 of 14 patients. HIV RNA >500 copies/mL at week 12 of first HAART predicts incomplete virologic response in patients with high levels of replication at baseline. Most patients carried resistance mutations at the time of failure.

Keywords

HIV HAART high viral load virologic failure resistance mutations

References

Wood E. , Hogg R. , Yip B. , et al. Higher baseline levels of plasma HIV type 1 RNA are associated with increased mortality after initiation of triple-drug antiretroviral therapy . J Infect Dis. 2003;188(10): 1421-1425.

Mussini C. , Manzardo C. , Johnson M. , et al, for the Late Presenter Investigators. Patients presenting with AIDS in the HAART era: a collaborative cohort analysis . AIDS. 2008;22(18):2461-2469.

Lima V. , Harrigan R. , Murray M. , et al. Differential impact of adherence on long-term treatment response among naïve HIV-infected individuals. AIDS. 2008;22(17):2371-2380.

Metzner K. , Allers K. , Rauch P. , Harrer T. Rapid selection of drug-resistant HIV-1 during the first months of suppressive ART in treatment-naïve patients. AIDS. 2007;21(6):703-711.

DHSS Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. http://AIDSInfo.nih.gov. Accessed November 3, 2008.

Metzner KJ , Giulieri SG , Knoepfel SA , et al. Minority quasispecies of drug-resistant HIV-1 that lead to early therapy failure in treatment-naïve and adherent patients. Clin Infect Dis. 2009;48(2):239-247.

Riddler S. , Haubrich R. , DiRienzo G. , et al, for the AIDS Clinical Trials Group Study A5142 Team. Class-sparing regimens for initial treatment of HIV-1 infection. N Engl J Med. 2008;358(20): 2095-2106.

Von Wyl V. , Yerli S. , Boni J. , et al, for the Swiss HIV Cohort Study. Emergence of HIV-1 drug resistance in previously untreated patients initiating combination antiretroviral treatment: a comparison of different regimen types. Arch Intern Med. 2007;167(16): 1782-1790.

Gupta R. , Hill A. , Sawyer AW , Pillay D. Emergence of drug resistance in HIV type 1-infected patients after receipt of first-line highly active antiretroviral therapy: a systematic review of clinical trials. Clin Infect Dis. 2008;47(5):712-22.

10.

Bartlett JA , Buda JJ , von Cheele B. , et al. Minimizing resistance consequences after virological failure on initial combination therapy: a systematic overview . J Acquir Immune Defic Syndr. 2006; 41(3):323-331.

11.

Conway B. The role of adherence to antiretroviral therapy in the management of HIV infection . J Acquir Immune Defic Syndr. 2007;45(suppl 1):S14-S18.